Despite the availability of safe and efficacious treatments, depression remains a significant healthcare issue for the elderly and is associated with functional decline, diminished quality of life, mortality from comorbid medical conditions or suicide, demands on caregivers, and increased service utilization.
Mount Sinai School of Medicine designates this Continuing Medical Education activity for a maximum of 1.0 Category 1 credit(s) toward the AMA Physician’s Recognition Award.
Widowhood is particularly common in the elderly, especially in women: ~41% of women identified four trajectories of grief and depression from pre-loss to 48 months post-loss.
The most common group of mourners (40%) were actually “resilient” and did not experience much depression or grief as demonstrated by scores on the Center for Epidemiologic Studies Depression scale.
Elderly individuals respond well to standard pharmacotherapy and psychotherapy treatments for depression.
However, due to the high rate of relapse of depression in this population, continuous treatment is often warranted.
Depression affects 6.5 million of the 35 million Americans ≥65 years of age.
It is an evolving mental state that changes as people cope with the different feelings and the new way that they need to live after someone that they love has died.Depression in the elderly is associated with impairment, dependency, disability, and significant distress for the individual and their family.This population is likely to present with concomitant cognitive dysfunction and medical illness, which can complicate the identification and treatment of psychiatric conditions.He is a consultant to Forest; on the speaker’s bureaus of Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, Glaxo Smith Kline, Janssen, and Pfizer; and receives grant/research support from Cephalon and Forest. Lenze is assistant professor of psychiatry at the University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, in Pennsylvania.He has received grant/research support from Janssen and Pfizer. Roose is professor of clinical psychiatry at the College of Physicians and Surgeons at Columbia University in New York City.